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We previously showed that cAMP can inhibit DNA damage-induced wild type p53 accumulation in
human pre-B NALM-6 cells, leading to a profound reduction of their apoptotic response. Here, we
provide evidence for the potentiation of DNA damage-induced NF-jB activation by cAMP. We found
that inhibition of NF-jB activation prevents the inhibitory effect of cAMP on doxorubicin-induced
apoptosis. Moreover, cAMP exerts its inhibitory effect on doxorubicin-induced apoptosis in a PKA-
independent manner. The present study also shows that elevation of cAMP prolongs the phosphor-
ylation of IjB and subsequent activation of NF-jB in doxorubicin treated NALM-6 cells in a protea-
some-dependent manner. Taken together, our results demonstrate that cAMP abrogates the balance
between apoptotic and antiapoptotic transcription factors that are hallmarks of DNA damage
signaling.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The sensitivity of tumor cells to apoptosis induced by DNA dam-
aging agents depends on the balance between apoptotic and anti-
apoptotic signals. Many cellular stimuli such as DNA damage result
in the induction of both the tumor suppressor p53 and NF-jB [1].
In contrast to activation of p53, which is associated with the induc-
tion of apoptosis, stimulation of NF-jB has been shown to promote
resistance to apoptosis [2,3]. However, in some other situations,
NF-jB appears to be proapoptotic [4]. We and others have recently
shown that elevation of cAMP reduces p53 accumulation and
apoptosis induced by DNA damage through an uncertain mecha-
nism [5,6]. In this study, we investigated the effect of cAMP on
DNA damage-induced NF-jB activation.
DNA damage can be detected by the sensors of DNA lesions,
which in turn recruit two major kinases capable of transducing
DNA damage signals, ataxia telangiectasia mutated (ATM), ataxia
telangiectasia and Rad3 related (ATR). In response to DNA damage,chemical Societies. Published by E
sic Medical Sciences, National
ulty of Nutrition Sciences and
l Sciences, P.O. Box # 19395-
and@gmail.com (H. Zand).
k.ATM phosphorylates a number of downstream effectors proteins
and kinases such as the checkpoint kinases1 (Chk1) and Chk2,
Mdm2 and p53, which regulate cell-cycle arrest, DNA repair, cell
senescence and apoptosis [7]. It has been demonstrated that ATM
is also essential for NF-jB activation by multiple genotoxic agents
that induce DNA double strand breaks (DSBs), including ionizing
radiation (IR), and the topoisomerase I and II inhibitors [8,9]. NF-
jB essential modulator (NEMO), the regulatory subunit of I kappa
B kinases (IKKs) complex, enters the nucleus and associates with
the DSB-activated ATM after the induction of DNA damage. The
subsequent ATM-dependent phosphorylation of NEMO at serine
85 is critical for further NEMO modification by ubiquitin, NEMO
nuclear export and activation of cytoplasmic IKK complex [10].
The present study analyzed the capacity of cAMP increasing
agents to modulate the toxicity of DNA topoisomerase II inhibitor
(doxorubicin) in human Pre-B NALM-6 cells. These cells possess
two characteristics important for regulation of apoptosis induced
by DNA damage, namely a constituent NF-jB expression and wild
type p53. Exploration of the cross-talk processes that link signaling
systems in defined cell types is crucial to our understanding of cell
function in health and disease and thus developing new diagnostic
methodologies and therapeutics. The present study offers novel
processes that provide connections between DNA damage signal-
ing and cAMP pathways.lsevier B.V. All rights reserved.
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2.1. Reagents and antibodies
Doxorubicin, forskolin, 3-isobutyl-1-methylxanthine (IBMX),
MG-132, H89, Bay 11-7082 and 3-(4,5-methylthiazol-2-yl)-2,5-di-
phenyl-tetrazolium bromide (MTT) were purchased from Sigma
(Sigma; St. Louis, MO). 8-CPT-cAMP was obtained from Santa Cruz
Biotechnology (Santa Cruz Biotechnology, CA). All primary anti-
bodies were obtained from Santa Cruz Biotechnology except cas-
pase-3 (8G10) and cleaved PARP (Asp214), which were obtained
from Cell Signaling Technology (Beverly, MA).
2.2. Cell culture
NALM-6 (human pre-B ALL) cells were grown in suspension in
RPMI medium supplemented with 2 mM L-glutamine, 10% FBS,
100 units/ml penicillin and 100 lg/ml streptomycin.
2.3. Detection of cell death by MTT colorimetric assay
The cell viability was determined using MTT assay [11]. Briefly,
NALM-6 cells were seeded at 5000/well in flat-bottom 96-well cul-
ture plates. The cells were preincubated with or without Bay 11-
7082 for 30 min before treatment with forskolin and IBMX for
30 min. Then they were treated with several concentrations of
doxorubicin and harvested after 24 h. After removing of the med-
ium, the cells were incubated with MTT solution (5 mg/ml in
PBS) for 4 h and the resulting formazan was solubilized with DMSO
(100 ll). The absorption was measured at 570 nm (620 nm as a ref-
erence) in an ELISA reader.
2.4. Apoptosis assay
To explore the effect of elevated cAMP on doxorubicin-induced
cell death, the cells were subjected to apoptosis analysis. Briefly,
the cells were seeded into 12-well cell culture plates and treated
with Bay 11-7082 (4 lM) for 30 min prior to addition of forskolin
(50 lM) and IBMX (100 lM) or 8-CPT-cAMP (200 lM). After
30 min, the cells were incubated with doxorubicin (0.5 lM) for
16 h and then collected. The cell aliquots were washed with PBS
and 106 cells were stained using Annexin V-FLOUS-Staining Kit
(Roche, Germany) according to the manufacturer’s instructions.
The percentage of apoptotic cells was quantified using Becton–
Dickinson FACS. Annexin V-positive and PI-negative cells were
considered to be in the early apoptotic phase and those having po-
sitive staining both for Annexin V and PI were deemed to undergo
late apoptosis or necrosis.
2.5. Nuclear fragmentation
The preparation of nuclear extracts was performed using the
Nuclear Extract Kit (Active Motif, Carlsbad, CA). NALM-6 cells
(4  106) were washed with 1 ml ice-cold PBS/phosphatase inhib-
itors, lysed in 250 ll hypotonic buffer and then centrifuged at
14 000g for 30 s at 4 C. The cell pellets were resuspended in
30 ll complete lysis buffer and centrifuged at 14 000g for
10 min at 4 C. Finally, the supernatants (nuclear fraction) were
saved.
2.6. NF-jB DNA-binding assay
The DNA-binding activity of NF-jB was quantified in the NALM-
6 cells by TransAMTM NF-jB p65 Transcription Factor Assay Kit
(Active Motif) according to the manufacturer’s instructions. Briefly,equal amounts of the nuclear extracts were incubated in 96-well
plates coated with immobilized oligonucleotide (50-AGTTGAGGG-
GACTTTCCCAGGC-30) containing a consensus (50-GGGACTTTCC-30)
binding site for the p65 subunit of NF-jB. NF-jB binding to the tar-
get oligonucleotide was detected by incubation with primary anti-
body specific for p65 subunit and HRP-conjugated secondary
antibody. For quantification of NF-jB activity, the optical densities
were measured at 450 nm by a microplate reader.
2.7. Western blot analysis
The cells were lysed in RIPA buffer (50 mM Tris [pH 7.5],
150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5 mM EDTA, 10 mM NaF,
5 mM b-glycerophosphate, 0.1 mM Na3VO4, 0.2 mM phenylmeth-
ylsulfonyl fluoride [PMSF], 10 mg/ml leupeptin and 0.5% aprotinin)
and the protein concentrations were determined using the Brad-
ford method (Bio-Rad). Equal amounts of the proteins were sepa-
rated on a 10% SDS–PAGE and subsequently transferred into a
nitrocellulose membrane (Amersham Pharmacia Biotech) using a
semidry transfer cell (Bio-Rad). The proteins were detected using
appropriate primary antibodies and the enhanced chemi-lumines-
cence detection system (ECL Plus, Amersham Pharmacia Biotech)
according to the manufacturer’s protocol.
2.8. Statistical analysis
SPSS 12 software was used to perform statistical analyses. The
significance of differences between the experimental variables
was determined by the use of two tailed Student’s t-test. A proba-
bility level of P > 0.05 was considered as statistically significant.
3. Results
3.1. Inhibition of NF-jB activation prevents the antiapoptotic effect of
cAMP in NALM-6 cells treated by doxorubicin
To reveal the effect of cAMP on NF-jB signaling, we first exam-
ined the effects of cAMP on the apoptosis induced by doxorubicin
in the presence of Bay 11-7082, an inhibitor of IjB phosphorylation
and NF-jB activation. As shown in Fig. 1A, the MTT assay analysis
showed that the cAMP increasing agents markedly reduce doxoru-
bicin-induced cell death, however, exposure of the cells to Bay
11-7082 (4 lM) dramatically reverses the inhibitory effect of
8-CPT-cAMP (200 lM), forskolin (50 lM) and IBMX (100 lM) on
the cytotoxicity of doxorubicin. These observations indicate that
cAMP may positively regulate the activation of NF-jB.
To address whether attenuation of doxorubicin-induced apop-
tosis by cAMP can be prevented by NF-jB inhibition in NALM-6,
we performed Annexin V staining of the NALM-6 cells exposed to
doxorubicin (0.5 lM) in the presence or absence of both cAMP
and Bay 11-7082 (4 lM). As shown in Fig. 1B, the percentage
of annexin V-positive cells in the cultures of NALM-6 cells
cotreated with doxorubicin and cAMP is profoundly lower than
that of the doxorubicin treated cells after 16 h, however, inhibi-
tion of NF-jB using Bay 11-7082 (4 lM) completely restores
early apoptotic features of doxorubicin even more than doxorubi-
cin alone.
A previous study from this laboratory demonstrated that p53
was induced 2-4 h after treatment with 0.5 lM doxorubicin, how-
ever, elevation of cAMP 30 min prior to doxorubicin exposure
attenuated p53 accumulation and DNA damage- induced apopto-
sis. The results of the present study also showed that attenuation
of p53 phosphorylation at Ser15 and its subsequent accumulation
persisted even after 18 h treatment with doxorubicin in the

























































































































































































































Full length caspase 3 (35kDa)
Cleaved caspase 3 (19/17kDa)
Cleaved PARP
Fig. 1. Inhibition of NF-jB activation reduces the antiapoptotic effects of cAMP in the NALM-6 cells exposed to doxorubicin. (A) NALM-6 cells were preincubated with or
without Bay 11-7082 (Bay, 4 lM) for 30 min before treatment with forskolin (F, 50 lM), IBMX (I, 100 lM) or 8-CPT-cAMP (8-CPT 200 lM) for 30 min. The cells were then
exposed to various concentrations of doxorubicin (Dox), harvested at 24 h post doxorubicin exposure and analyzed by MTT assay as indicated in the Section 2. Each data point
presented is an average of the measurements from 5 wells. The values represented as mean ± S.E. (n = 3; *P < 0.05; P < 0.01 relative to the cells treated with doxorubicin only).
(B) The NALM-6 cells were treated with Bay 11-7082 (4 lM) for 30 min prior to addition of forskolin (50 lM) and IBMX (100 lM) or 8-CPT-cAMP (200 lM). After 30 min, the
cells were incubated with doxorubicin (0.5 lM) for 16 h and then assayed for cell death using Annexin V staining. The percentage of Annexin V-positive cells was analyzed by
FACS. Each value represented the average of three independent experiments ± S.E. (n = 3; *P < 0.05; P < 0.01 relative to the cells treated with doxorubicin only). (C) The
inhibitory effect of cAMP on p53 and downstream signaling. Immunoblot analysis was performed using specific antibodies, to investigate the effect of cAMP increasing agents
on the level of p53, Phospho-p53 (Ser15), p21 and cleavage of caspase-3 and PARP induced by doxorubicin,. The NALM-6 cells (0.5–0.8  106) were treated by doxorubicin
(0.5 lM) for 16 h in the presence and absence of forskolin (F), IBMX (I) and 8-CPT-cAMP (8-CPT). Equal amounts of the cell lysates were subjected to Western blot analysis
using the indicated antibodies. An anti-actin antibody was used to ensure equal loading and quality of the protein extracts.
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direct target of p53 and a component of the DNA damage-induced
G1 arrest response, was also reduced in the NALM-6 cells treated
by doxorubicin in the presences of forskolin, IBMX and 8-CPT-
cAMP (Fig. 1C). Western blot analysis indicated that activation
and cleavage of caspase-3 in apoptosis induced by doxorubicin
was blocked by the elevation of intracellular cAMP. Activation of
caspase-3 leads to the cleavage of a number of proteins, one of
which is Poly (ADP-ribose) polymerase (PARP) [12]. These results
were also confirmed by observation of PARP cleavage during the
apoptosis induced by doxorubicin in the presence or absence of
cAMP (Fig. 1C). Taken together, these results show that elevation
of cAMP decreases p53-mediated apoptosis and inhibition of NF-
jB blocks the inhibitory effect of cAMP on the apoptosis induced
by doxorubicin.3.2. The inhibitory effect of cAMP on doxorubicin-induced apoptosis is
not exerted through cAMP dependent protein kinase (PKA)
In the eukaryotic cells, PKA is a key enzyme in signal transduc-
tion, representing the main target of the second messenger cAMP.
Therefore, we wished to investigate whether inhibition of PKA by
H89 affected the inhibitory effect of cAMP on the apoptosis in-
duced by doxorubicin. To do so, the NALM-6 cells were preincu-
bated with or without H89 (30 lM) for 30 min before treatment
with forskolin and IBMX for 30 min. The cells were then exposed
to doxorubicin, harvested after 16 h and then analyzed for Annex-
in V uptake by FACS. To confirm the inhibition of PKA by H89, we
assessed the effect of H89 on the extent of cAMP responsive ele-
ment binding (CREB) phosphorylation, as a recognized target of
PKA [13], by immunoblot analysis. To this end, the NALM-6 cells
M. Safa et al. / FEBS Letters 584 (2010) 3492–3498 3495were preincubated with H89 30 min before forskolin and IBMX
treatment. The cell were then treated by doxorubicin for
30 min, harvested and subjected to immunoblot analysis with
phospho-specific antibodies against CREB phosphorylated at
Ser133. As can be seen in Fig. 2A, preincubation of the cells with
forskolin and IBMX leads to a significant inhibition of the apopto-
sis induced by doxorubicin. In contrast, pretreatment of the cells
with 30 lM H89 could not prevent the inhibitory effect of for-
skolin and IBMX on the doxorubicin-induced apoptosis. As
showed in Fig. 2B, preincubation of the NALM-6 cells by 30 lM
H89 completely prevents the forskolin/IBMX-induced CREB phos-
phorylation. These results indicate that H89 (30 lM) could inhibit
PKA function in these experiments.
3.3. Elevation of intracellular cAMP prolong doxorubicin-induced
phosphorylation and subsequent degradation of IjB
Almost all signals that lead to activation of NF-jB, converge on
the activation of a high molecular weight complex that contains a
serine-specific IjB kinase (IKKs). Activation of IKKs, in turn, leads
to site-specific phosphorylation of IjB and its degradation by the
ubiquitin–proteasome pathway allowing nuclear translocation of
NF-jB. The DNA damage-induced phosphorylation of IjB at Ser32
and Ser36 has been proposed to contribute to promote NF-jB acti-
vation [14]. This together with our present finding that the inhibi-
tion of IjB phosphorylation prevents the inhibitory effect of cAMP
on doxorubicin-induced apoptosis, suggest that phosphorylation of
IjB has major role in the antiapoptotic effect of cAMP. Therefore,
we wished to investigate whether cAMP enhances doxorubicin-in-
duced NF-jB DNA-binding by positive regulation of IjB phosphor-



























































Fig. 2. cAMP exerts its effect on doxorubicin-induced apoptosis through a PKA-
independent mechanism. (A) The NALM-6 cells were treated with H89 (30 lM) for
30 min prior to the addition of IBMX and forskolin. After 30 min, the cells were
exposed to doxorubicin (0.5 lM) and incubated for an additional 16 h. The cells
were then assayed for cell death using Annexin V staining. The percentage of
Annexin V-positive cells was analyzed by FACS. Each value represents the average
of three independent experiments ± S.E. (B) The NALM-6 cells were treated with
H89 (30 lM) for 30 min prior to the addition of IBMX and forskolin. After 30 min,
the cells were exposed to doxorubicin and incubated for an additional 30 min. The
whole cell lysates were then prepared and analyzed by immunoblotting with the p-
CREB (Ser133) and anti-actin antibodies as positive control. The immunoblot shows
one representative experiment out of three independent experiments.end, the NALM-6 cells were treated with doxorubicin in the pres-
ence or absence of forskolin and IBMX, harvested at several inter-
vals up to 24 h and then subjected to western blotting by the
antibodies directed toward IjB phosphorylated at Ser32 and IjBa.
As shown in Fig. 3, phosphorylation of IjB was induced in the ab-
sence of cAMP by 2 h after doxorubicin incubation, reached its
maximum level within 6 h and progressively declined by the end-
point of the experiment at 24 h. Preincubation of the NALM-6 cells
with forskolin and IBMX prior to doxorubicin exposure caused an
alteration in the phosphorylation pattern of IjB. While, in the pres-
ence of cAMP, the phosphorylation of IjB was induced after a lag
time of about 4 h and triggered by 6 h after DNA damage-induced
by doxorubicin. Then it reached its maximum level within 8 h and
remained relatively constant at this level up to 24 h. Moreover, we
showed that in spite of the early inhibition of degradation, doxoru-
bicin-induced degradation of IjB was prolonged in compare to the
NALM-6 cells treated by doxorubicin alone (Fig. 3, the middle
panel).
3.4. cAMP prolongs IjB degradation and NF-jB activation induced by
doxorubicin in a proteasome-dependent manner
NF-jB activation induced by DNA damage pathway involves the
rapid phosphorylation of IjBa at Ser32 and Ser36 by IKKs and sub-
sequent ubiquitin- induced degradation by 26S proteasome. There-
fore, to further characterize the mechanism by which cAMP utilizes
proteasome to exert its stimulatory effect on NF-jB, we examined
the effect of cAMP on IjB level in the presence of the proteasome
inhibitor, MG-132, by western immunoblot analysis. As shown in
Fig. 4, preincubation of NALM-6 cells with MG-132 (20 lM) pre-
vented the stimulatory effect of forskolin and IBMX on the doxoru-
bicin- induced degradation of IjB. As already mentioned, in the
absence of proteasome inhibitor (MG-132), cAMP prolongs phos-
phorylation and subsequent catabolism of IjB-induced by doxoru-
bicin. Our finding also showed that preincubation with MG-132
caused a slightly increase in phosphorylation of IjBa at Ser32
(Fig. 4, the middle panel). These observations indicate that phos-
phorylation of IjBa is not affected by inhibition of proteasome.
3.5. In spite of early inhibition, the cAMP increasing agents potentiate
NF-jB DNA-binding activity induced by doxorubicin
Since our results showed that cAMP increasing agents prolong
IjB phosphorylation induced by doxorubicin, therefore, we wished
to verify whether NF-jB DNA-binding activity also is potentiated
by elevation of cAMP in the NALM-6 cells treated by doxorubicin
using NF-jB activity assay kit. For this purpose, we examined the
effect of forskolin and IBMX on DNA damage- induced NF-jB activ-
ity in the presence or absence of Bay 11-7082. As indicated in
Fig. 5A, the DNA-binding of NF-jB increased rapidly and reached
its maximum level within 4–8 h following the doxorubicin treat-
ment. NF-jB activity then gradually decreased up to 24 h. How-
ever, in the presence of forskolin and IBMX, we observed a delay
in NF-jB/p65 DNA-binding until 4–6 h of doxorubicin treatment
followed by an immediate increase in NF-jB activity up to 24 h.
In the presence of Bay 11-7082, cAMP showed no effect on NF-
jB activity during the DNA damage.
We then examined whether cAMP affected proapoptotic genes
regulated by NF-jB. To this end, prior to doxorubicin incubation
in absence or presence of forskolin and IBMX, the NALM-6 cells
were treated by Bay 11-7082 to inhibit NF-jB activity. The cells
were harvested for 24 h after doxorubicin incubation and then ana-
lyzed for the expression of XIAP and Bcl2 levels in the NALM-6 cells
by western blot. As shown in Fig. 5B, cAMP induced XIAP and Bcl2
expression in the cells treated by doxorubicin in a NF-jB depen-
dent manner. Inhibition of NF-jB activity using Bay 11-7082
Fig. 3. In spite of early delay, cAMP potentiates IjB phosphorylation and subsequent degradation in the NALM-6 cells incubated by doxorubicin. The NALM-6 cells were
preincubated with or without forskolin (F) and IBMX (I) 30 min before treatment with 0.5 lM doxorubicin. The cells were then harvested at the indicated times after
doxorubicin exposure and subjected to immunoblot analysis using IjB antibody and phospho-specific antibody against IjB phosphorylated at Ser32. As a loading control, b-
actin levels were determined (the bottom panel). One representative experiment of three is shown.
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Fig. 4. Stimulation of IjBa degradation induced by cAMP and doxorubicin is blocked by proteasome inhibitors. The NALM-6 cells were preincubated with or without MG-132
for 4 h before treatment with forskolin (F) and IBMX (I) for 30 min. The cells were then treated with doxorubicin, harvested at the indicated times after the doxorubicin
exposure, and subjected to immunoblot analysis using IjBa antibody and phospho-specific antibody against phosphorylated form of IjB at Ser32. As a loading control, b-actin
levels were determined (the bottom panel). One representative experiment of three is shown.
3496 M. Safa et al. / FEBS Letters 584 (2010) 3492–3498declined the expression of both proapoptotic proteins in the cells
cotreated by doxorubicin and cAMP.
Taken together, these results demonstrate that elevation of
intracellular cAMP prolongs NF-jB activity induced by doxorubicin
in NALM-6 cells.
4. Discussion
In the case of massive DNA damage, the affected cells can be de-
stroyed by initiating apoptosis. The transcription factor p53, also
known as the ‘‘guardian of the genome”, has a key function in
the activation of programmed cell death [2]. But it is not always
successful in switching on the apoptotic program. NF-jB often op-
poses the function of p53 and its activation triggers a survival pro-
gram that protects the damaged cells from destruction [15].
Activation of NF-jB following genotoxic stress provides an oppor-
tunity for DNA-damage repair and ensures cell survival. The activa-
tion of this program by NF-jB is considered to be one of the
possible causes for the resistance of tumor cells to chemo- or radi-
ation-therapy [16].
Recently, we reported that elevation of cAMP, prior to DNA
damage, decreases phosphorylation of key sites in p53, which are
pivotal for the release of p53 from Hdm2, translocation into nu-
cleus and subsequent p53-induced apoptosis [10]. Surprisingly,
in the present study, our observations showed that PKA, as the ma-
jor target of cAMP, did not mediate the inhibitory effect of cAMP on
the apoptosis induced by doxorubicin. This study also provided
evidence, for the first time, that doxorubicin-induced NF-jB acti-
vation was prolonged by elevation of cAMP in the NALM-6 human
pre-B cells that express wild type p53. This potentiation of NF-jB
activation occurs through the enhancement of IjB phosphorylation
and its subsequent degradation in a proteasome-dependent man-ner. Our results also showed that inhibition of NF-jB activation
using Bay 11-7082 profoundly reverses the inhibitory effect of
cAMP on the doxorubicin-induced apoptosis. Further, based on
our findings, although cAMP targets both p53 and NF-jB signalings
triggered by doxorubicin in the NALM-6 cells to inhibit apoptosis,
NF-jB still retains its key position as a chemoresistance factor.
Several lines of evidence indicate that NF-jB has antiapoptotic
role during the DNA damage and inhibition of constitutive and that
DNA damage-induced NF-jB activation enhances apoptosis in-
duced by DNA damaging agents [17,18]. Although there is some
evidence indicating that the transcriptional activity of NF-jB is
stimulated upon phosphorylation of its p65 subunit by PKA and
modulation of its interaction with CBP/p300 [19], other studies
have shown that cAMP/PKA inhibits NF-jB-mediated transcription
in human monocytic cells and endothelial cells [20]. Our results
using PKA inhibitor, H89, did not support this idea that PKA medi-
ates antiapoptotic effect of cAMP in the apoptosis induced by doxo-
rubicin. We also observed that the inhibition of PKA by H89 had no
effect on IjB degradation induced by doxorubicin (data not
shown). We observed that doxorubicin-induced phosphorylation
of IjB and subsequent activation of NF-jB were initiated with a
delay of 2–4 h in the presence of cAMP. It can be attributed to
the pleiotropic effect of cAMP and multiple targets of this second
messenger.
It has been shown that Epac has also been implicated in regulat-
ing of various cellular processes, notably playing an antiapoptotic
role in B-chronic lymphocytic leukaemia cells (B-CLL) [21] and T-
ALL cells [22]. However, selective agonist of Epac had no inhibitory
effect on the apoptosis induced by doxorubicin in the NALM-6 cells
(unpublished data). These results seem to raise a possible role for
the third target of cAMP, i.e. cyclic nucleotide-gated (CNG) cation
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Fig. 5. cAMP increases the induction of NF-jB DNA-binding activity by doxorubicin.
(A) The NALM-6 cells were treated with or without NF-jB inhibitor, Bay 11-7082
(4 lM) for 30 min before treatment with forskolin (F) and IBMX (I) for 30 min. The
cells were then incubated with doxorubicin and harvested at the indicated times
after doxorubicin incubation. Then the nuclear fraction was separated using
Nuclear Extraction Kit. NF-jB activity was quantified by enzyme-linked immuno-
sorbent assay using the TransAM NF-B p65 Transcription Factor Assay Kit, according
to the manufacturer’s instructions. Values represented as mean ± S.E. (B) The
NALM-6 cells were treated with Bay 11-7082 (4 lM) for 30 min prior to the
addition of forskolin and IBMX (F + I). After 30 min, the cells were exposed to
doxorubicin (0.5 lM) and incubated for an additional 24 h. The cells were then
harvested and subjected to immunoblot analysis using specific antibodies against
XIAP and Bcl2. An anti-actin antibody was used to ensure equal loading and quality
of the protein extracts. These are the representative data of more than two
experiments.
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duced by DNA damage, or whether Ca+2 dependent cysteine prote-
ases, calpains, are the main mediators of degradation of p53 and
IjB, is still debated. Although, inhibition of proteasome using
MG-132 completely prevented the inhibitory effect of cAMP on
doxorubicin-induced NF-jB activation, it has been shown that
MG-132 can also inhibit calpains activity [24]. It has been sug-
gested that p53 and IjB are substrates for degradation by calcium
dependent calpains [25,26]. Further investigations are in progress
in our lab to study the role of CNG and intracellular calcium in
DNA damage.
Since our findings indicated that cAMP downregulated doxoru-
bicin-induced p53 and potentiates NF-jB activation, a question
emerges: how much is the contribution of p53 destabilization
and NF-jB activation in the inhibitory effect of cAMP in doxorubi-
cin-induced apoptosis. It has been shown that p53 and NF-jB RelA
activated by genotoxic stress mutually suppress each other’s abil-
ity to activate transcription, most likely through competition for
transcriptional coactivators such as CBP or p300 [27,28]. Therefore,
the inhibition of p53 function and the secondary activation of NF-
jB are among the possible mechanisms responsible for the inhib-
itory action cAMP on DNA damage-induced apoptosis. Recently,
Naderi et al. demonstrated that inhibitory effect of cAMP on gam-
ma-radiation-induced apoptosis is p53 dependent in human pre-BReh cells [5]. Although, these results indicate that functional p53
might be required for the inhibitory effect of cAMP on DNA dam-
age-induced apoptosis, our results showed that potentiation of
doxorubicin-induced NF-jB activation by cAMP is also important
in the inhibitory effect of cAMP on the apoptosis induced by doxo-
rubicin. These results further support the notion that NF-jB activa-
tion has a major role in regulation of DNA damage pathway.
We preincubated the cells with pharmacological agents to ele-
vate intracellular cAMP in NALM-6 cells, although these results
can be also generalized under in vivo conditions of tumor cells.
In most of tumor cells cyclooxygenase-2 (COX-2) is overexpressed.
Also prostaglandins (PGs) such as PGE2 are produced at heightened
levels in these tumors. PGE2 exerts its biological action through
elevation of cAMP in a paracrine manner [29]. Therefore, this sur-
vival action of cAMP seems to be very important for malignant cells
in vivo.5. Conclusion
Given the importance of NF-jB in immune-cell function, it is
not all that surprising that it is involved in the development of such
cancers. The present study demonstrated that cAMP increasing
agents inhibit p53 accumulation and prolong NF-jB activation
during the DNA damage inflicted by doxorubicin. Our results also
showed that cAMP can be considered as a survival factor for DNA
damaging agents. The complexity of these signaling systems may
require additional studies to resolve the connections that serve
to integrate cellular responses through these pathways.
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